Abstract:Background: Furosemide is a commonly used loop diuretic in critical care. However, its effect on the progression of oliguric acute kidney injury across different central venous pressure (CVP) remains unknown. This study therefore aims to investigate the association between furosemide(6-12h ) (defined as the use of furosemide within 6 h after the diagnosis of AKI according to the urine output [UO] criteria set by the Kidney Disease: Improving Global Outcomes [KDIGO] guidelines) and the progression of AKI across different CVP6-12h (defined as CVP within 6 h after the diagnosis of AKI by the KDIGO UO criteria) levels. Methods: Patients involved in this study were identified from the Medical Information Mart for Intensive Care IV database with the following criteria: (i) adults with UO < 0.5 mL/kg per hour for the first 6 h upon admission to the intensive care unit (ICU) (meeting stage 1 AKI by UO) and (ii) CVP6-12h ranging from 0 to 30 mm Hg. From there on, the target primary outcome would be progression to stage 3 AKI by UO among these chosen patients. The secondary outcome was 28-d mortality since ICU admission. The risks of severe-stage AKI progression and 28-d mortality were respectively examined against furosemide(6-12h ) (vs. without furosemide6-12h) within the full cohort and across different subgroups of CV6-12h , using multivariate adjusted logistic regression and inverse probability treatment weighting (IPTW). Sensitivity analyses were performed to assess the robustness of our findings. Results: One thousand one hundred eighty patients were ultimately selected for this study, of whom 643 (54.5%) progressed to stage 3 AKI from stage 1 based on the UO criteria by KDIGO. Multivariate analysis showed that furosemide(6-12h ) is significantly associated with this severe-stage progression within the full cohort (odds ratio [OR] was 0.62 at 95% confidence interval [CI] of 0.43-0.90, P = 0.011). After dividing the patients into CVP6-12h subgroups according to their CVP during the early phases, lower risk of AKI progression was observed only in furosemide(6-12h ) application at CVP6-12h of > 12 mm Hg (adjusted OR was 0.40 at 95% CI of 0.25-0.65, P < 0.001), as confirmed by the IPTW analysis (OR was 0.47 at 95% CI of 0.29-0.76, P = 0.002). The robustness of these findings was confirmed by sensitivity analyses. In addition, for patients with CVP6-12h > 12 mm Hg, furosemide(6-12h ) is also significantly associated with lower risk of 28-d mortality (adjusted OR was 0.47 at 95% CI of 0.25-0.92, P = 0.026) in the multivariate logistic regression analysis, and there was a similar trend in the IPTW analysis (adjusted OR was 0.55 at 95% CI of 0.28-1.10, P = 0.092). Conclusions: Among the identified early-stage AKI patients in critical care, the use of furosemide was associated only with lower risk of oliguric AKI progression and 28-d mortality within the high CVP group. These findings suggest the potential of CVP as a guidance or reference point in the usage of furosemide among early-stage oliguric AKI patients in the ICU.

Effects of low-dose furosemide combined with aminophylline on the renal function in septic shock patients

Effects and Safety of Separate Low-Dose Hydrocortisone Use in Patients with Septic Shock: A Meta-Analysis

Association Between Furosemide Administration and Outcomes in Critically Ill Patients with Acute Kidney Injury.

Association between furosemide administration and clinical outcomes in patients with sepsis-associated acute kidney injury receiving renal replacement therapy: a retrospective observational cohort study based on MIMIC-IV database

Effectiveness of Anisodamine for the Treatment of Critically Ill Patients with Septic Shock (acidosis Study): Study Protocol for Randomized Controlled Trial

Effect of Dopamine and Metaraminol on the Renal Function of Patients with Septic Shock

The effects of early-phase furosemide use on the progression of oliguric acute kidney injury across different central venous pressure: a retrospective analysis

Effectiveness of anisodamine for the treatment of critically ill patients with septic shock: a multicentre randomized controlled trial

Effect of the Intensity of Continuous Renal Replacement Therapy in Patients with Sepsis and Acute Kidney Injury: a Single-Center Randomized Clinical Trial

High Dose Of Furosemide Associated With Severe Acid-Base Disturbances In Treatment Of Critically Ill Patients: A Retrospective Observation Analysis

Application effect of furosemide combined with vasoactive drugs in cardio-renal syndrome: a systematic review

Effect of furosemide combined with continuous renal replacement therapy on cardiorenal function and inflammatory response in patients with chronic renal and heart failure after hemodialysis

Outcomes of Bolus Dose Furosemide Versus Continuous Infusion in Patients With Acute Decompensated Left Ventricular Failure and Atrial Fibrillation

Effect of Continuous Furosemide Infusion on Outcome of Acute Kidney Injury.

Effect of Combining Furosemide With Standard Hydration Therapy on Contrast-Induced Acute Kidney Injury Following Coronary Angiography or Intervention in a High-Risk Population

Effect of dopamine on the renal function in the patients with septic shock

The Effects of Early Restrictive Fluid Resuscitation on the Clinical Outcomes in Sepsis Patients

Effect of the combination of HA380 hemoperfusion with CVVHDF on inflammatory indices and microcirculation in early septic shock

Effect of Metaraminol on Arterial Blood Pressure and Renal Function in Patients with Septic Shock

Comparison of bumetanide- and metolazone-based diuretic regimens to furosemide in acute heart failure

Impact of Colloid Infusion on Outcomes in Patients with Septic Shock